Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25228718 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25272099 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25227720 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25270374 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25277072 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25270460 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25277227 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25269680 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25272251 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25227877 | 0.92 | CA12 (0.50) | CA12CA1CA9CA2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493583-B2 | Anionic polysaccharides functionalized by a hydrophobic acid derivative | ADOCIA (FR) | 2016-11-15 | — | — | US | claimed |
| EP-2516473-B1 | ANIONIC POLYSACCHARIDES FUNCTIONALISED WITH A DERIVATIVE OF HYDROPHOBIC ACID | ADOCIA (FR) | 2020-09-30 | — | — | EP | disclosed |
| US-9493583-B2 | Anionic polysaccharides functionalized by a hydrophobic acid derivative | ADOCIA (FR) | 2016-11-15 | — | — | US | disclosed |
| EP-2516473-A1 | ANIONIC POLYSACCHARIDES FUNCTIONALISED BY A HYDROPHOBIC ACID DERIVATIVE | Adocia (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20110172166-A1 | Anionic polysaccharides functionalized by a hydrophobic acid derivative | ADOCIA (FR) | 2011-07-14 | — | — | US | disclosed |
| WO-2011077405-A1 | ANIONIC POLYSACCHARIDES FUNCTIONALISED BY A HYDROPHOBIC ACID DERIVATIVE | ADOCIA (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172166-A1 | Anionic polysaccharides functionalized by a hydrophobic acid derivative | ALG1, CD44, FUT6 | CA12 371/4885CA1 1436/4885CA9 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.